These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 35715365)
1. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma. Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365 [TBL] [Abstract][Full Text] [Related]
2. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients. Choi Y; Keam B; Kim M; Yoon S; Kim D; Choi JG; Seo JY; Park I; Lee JL Cancer Res Treat; 2019 Oct; 51(4):1549-1556. PubMed ID: 30913859 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299 [TBL] [Abstract][Full Text] [Related]
5. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report. Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341 [TBL] [Abstract][Full Text] [Related]
6. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138 [TBL] [Abstract][Full Text] [Related]
8. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression. Anderson WJ; Tsai HK; Sholl LM; Hirsch MS Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731 [No Abstract] [Full Text] [Related]
9. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. Kotecha RR; Doshi SD; Knezevic A; Chaim J; Chen Y; Jacobi R; Zucker M; Reznik E; McHugh D; Shah NJ; Feld E; Aggen DH; Rafelson W; Xiao H; Carlo MI; Feldman DR; Lee CH; Motzer RJ; Voss MH Eur Urol Oncol; 2024 Aug; 7(4):804-811. PubMed ID: 37945488 [TBL] [Abstract][Full Text] [Related]
10. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242 [TBL] [Abstract][Full Text] [Related]
11. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas. Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712 [TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma. Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408 [TBL] [Abstract][Full Text] [Related]
20. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report. Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]